New Systematic Review Finds Fat Stem Cell Therapy Reduces Knee Pain by 44-62%

A new systematic review published in the Journal of Orthopaedic Surgery and Research suggests that combining micro-fragmented adipose tissue (MFAT) injections with knee arthroscopy may provide meaningful pain relief and functional improvement in knee osteoarthritis (KOA) patients, a population without many options.

Background: Regenerative Approaches Emerge for KOA

Knee osteoarthritis is a prevalent degenerative joint disorder, now increasingly seen not only among older adults but also in younger populations due to obesity and joint trauma. Current standard treatments, ranging from physical therapy to pharmaceuticals, often fall short, particularly in delaying or avoiding joint replacement.

Enter regenerative medicine: MFAT has potential due to its high concentration of mesenchymal stem cells (MSCs) and other growth factors known to support cartilage repair and reduce inflammation.

MFAT is often prepared via simple abdominal or thigh liposuction, then processed to retain cellular and bioactive elements for regeneration. When combined with arthroscopy, MFAT can be precisely delivered to affected areas. This review systematically assesses the efficacy and safety of such a combination for KOA.

In total, two randomized controlled trials and four retrospective studies, published between 2022 and 2025, were included.

Findings: Pain Relief and Functional Gains, with Limited Complications

Across all studies, patients who underwent MFAT injections during knee arthroscopy reported significant pain improvements, anywhere from a 44.4% to 62.2% reduction (via Visual Analog Scale). Improvements in joint function were also reported using WOMAC, KOOS, and Lysholm scores, though the magnitude varied from study to study.

Adverse effects were minimal overall. Most complications were mild, such as brief pain or swelling at the liposuction or injection site. A small number of cases involved lipoatrophy, joint effusion, or painful adipose nodules, but these were uncommon. No study reported severe or lasting adverse events related to the therapy.

Cartilage Health and Biomarker Outcomes

Some studies assessed the structural effects of the treatment. One research group utilized the Whole Organ Magnetic Resonance Imaging Score (WORMS) and found significant improvements in cartilage condition after the procedure. However, when bone metabolism markers (CTx-II, PIIINP) were measured, there were no marked changes following treatment. This suggests that while soft tissue repair was evident on imaging in some cohorts, the effects on underlying bone metabolism remain unclear from currently available data.

Limitations and Gaps in the Evidence

The authors of the review emphasize several major limitations, including a relatively few number of studies (six), follow-up durations generally short (12-48 months), and heterogeneity in methodologies, including rehab, outcome reporting, and lack of blinding in some studies, restrains the ‘generalizability’ of the findings.

Additionally, while nearly all outcomes favored the combined approach for pain and function, evidence regarding true cartilage regeneration, alterations in bone metabolism, and the durability of improvements is limited. The precise mechanisms by which MFAT, and particularly the MSC component, exerts its effects in the joint remain to be fully elucidated, with questions remaining about cell survival, engraftment, and long-term functional integration.

Future Directions: Toward Better Understanding and Implementation

The review’s authors highlight several directions for future investigation. For one, as with most regenerative medicine, we need more high-quality, large-scale RCTs with long-term follow-up. Additionally, we need more standardized MFAT processing methods and postoperative rehab protocols to clarify and optimize the therapy. Lastly, there are other combinations to consider, including platelet-rich plasma + MFAT, or other biologics.


References
Hu, X., Zhang, Z., Zhang, W. et al. Efficacy and safety of micro-fragmented adipose tissue combined with knee arthroscopy in the treatment of knee osteoarthritis: a systematic review. J Orthop Surg Res 20, 646 (2025). https://doi.org/10.1186/s13018-025-06006-5

If you found this post helpful, would you mind sharing it? ⬇️ 

Related:

The new registry aims to address evidence gaps and track long-term outcomes for orthobiologic treatments.
The proposed legislation, if passed, will allow culture-expanded autologous mesenchymal stem cell therapies in the Cowboy State.
The company's autologous cartilage repair product will now be reimbursed under national health insurance, WOMAC scores improved better than hyaluronic acid injections.
The trial found no significant difference in pain or function outcomes between bone marrow injections and sham procedures over 12 months, but also had important limitations.
FDA feedback suggests rexlemestrocel-L may reduce chronic back pain and opioid use, Phase 3 underway.

The Latest:

Lineage will evaluate the new gene-edited iPSC line for immune compatibility and manufacturing potential before pursuing exclusive rights with Factor Bioscience.
Long-term follow-up suggests ProTrans may help preserve insulin production, with results varying by dose.
The collaboration will assess whether robotic automation can help scale up cell therapy manufacturing while maintaining GMP standards.
The partnership aims to streamline production and quality testing of gene-edited hematopoietic stem cell therapies for HIV and rare diseases.
With the right secured for stem cell potency, Longeveron is continuing its path forward with clinical trials for several mesenchymal stem cell indications.
The new open source gene editing services are ready to help iPSC developers create off-the-shelf allogeneic cell therapies at scale.
Polyphron will use Cellino's induced pluripotent stem cells in its "autonomous tissue foundry" to reproducibly manufacture cell and tissue therapies at scale.
The new CellFiber Extruder aims to address manufacturing bottlenecks in cell therapy by enabling scalable, GMP-compliant cell production.
Based on Phase IIa trial data where 85% of patients had resolution of chronic fatigue over 20% with placebo, the company will now offer its cord blood cell therapy outside of the Phase III soon.
Researchers report that intranasal Muse cells improved motor function and reduced neurodegeneration in a Parkinson’s mouse model.
Stemchymal's CDMO has been selected, while the company seeks conditional approval in both Japan and Taiwan following Phase II results.
Resbiomed, a placental collagen materials manufacturer, is working on scaling up production for what appears regenerative ophthalmology in Europe.

Discover more from Regen Report

Subscribe now to keep reading and get access to the full archive.

Continue reading

Stay updated on Regenerative Medicine